- Title: Subtitle
- Health-related quality of life associated with every-3-week paclitaxel vs dose-dense weekly paclitaxel in combination with carboplatin with or without bevacizumab for primary ovarian cancer: Gynecologic Oncology Group study 262
- Creators
- B.J. Monk - University of ArizonaH. Huang - Gynecologic Oncology GroupR.T. Penson - Massachusetts General HospitalS.A. Davidson - University of Colorado DenverM.L. Pearl - Stony Brook University HospitalD.M. O'Malley - The Ohio State University, Columbus Cancer Council, Hilliard, OH, USAD.P. Bender - University of IowaM.P. Boente - Minnesota OncologyL.P. Martin - Fox Chase Cancer CenterJ.K. Chan - UCSF Helen Diller Family Comprehensive Cancer CenterJ.L. Walker - Oklahoma City UniversityC.K. McCourt - Women & Infants Hospital of Rhode Island
- Resource Type
- Abstract
- Publication Details
- Gynecologic oncology, Vol.133, pp.58-58
- Publisher
- Elsevier Inc
- DOI
- 10.1016/j.ygyno.2014.03.159
- ISSN
- 0090-8258
- eISSN
- 1095-6859
- Language
- English
- Date published
- 06/2014
- Academic Unit
- Obstetrics and Gynecology
- Record Identifier
- 9984317104902771
Abstract
Health-related quality of life associated with every-3-week paclitaxel vs dose-dense weekly paclitaxel in combination with carboplatin with or without bevacizumab for primary ovarian cancer: Gynecologic Oncology Group study 262
Gynecologic oncology, Vol.133, pp.58-58
06/2014
DOI: 10.1016/j.ygyno.2014.03.159
Details
Metrics
3 Record Views